Chandrasekhar Udata

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

John F. DiJoseph, Douglas Armellino, Erwin R. Boghaert et al. · Blood · 2003 · 356 citations · Full text

Medicine, Medicinal Chemistry, Oncology +11

Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants

Arie Katz, Chandrasekhar Udata, Elyssa Ott et al. · The Journal of Clinical Pharmacology · 2009 · 206 citations

Medicine, Pharmacokinetics, Pharmacology +16

Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII

Michael Recht, László Nemes, Michał Matysiak et al. · Haemophilia · 2009 · 93 citations

Medicine, Pharmacokinetics, Pharmacology +17

Reformulated B<scp>ene</scp>F<scp>ix</scp>^®: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B

Thierry Lambert, Michael Recht, Leonard A. Valentino et al. · Haemophilia · 2007 · 90 citations

Medicine, Pharmacokinetics, Pharmacology +11

ReFacto®¹ and Advate®²: a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A

Mark P. Smith, Robert Klamroth, P.M. Mannucci et al. · Haemophilia · 2007 · 50 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +14